Our findings suggest that the interaction between YAP and Bcl-2 family members can lead to synthetic lethality that would aid in overcoming drug resistance, and combined inhibition of these pathways might provide a selective and effective therapeutic strategy for highly metastatic GC with RASA1 and NF2 deficiency. Here, YAP1 is linked to gastric cancer.